Skip to main content
Top
Published in: Inflammation 6/2015

01-12-2015

Ox-LDL Upregulates IL-6 Expression by Enhancing NF-κB in an IGF2-Dependent Manner in THP-1 Macrophages

Authors: Yan-Chao Wang, Yan-Wei Hu, Yan-Hua Sha, Ji-Juan Gao, Xin Ma, Shu-Fen Li, Jia-Yi Zhao, Yu-Rong Qiu, Jing-Bo Lu, Chuan Huang, Jing-Jing Zhao, Lei Zheng, Qian Wang

Published in: Inflammation | Issue 6/2015

Login to get access

Abstract

Interleukin 6 (IL-6) is a pro-inflammatory cytokine that is well established as a vital factor in determining the risk of coronary heart disease and pathogenesis of atherosclerosis. Moreover, accumulating evidences have shown that oxidized low-density lipoprotein (ox-LDL) can promote IL-6 expression in macrophages. Nevertheless, the underlying mechanism of how ox-LDL upregulates IL-6 expression remains largely unexplained. We found that the expression of insulin-like growth factor 2 (IGF2), nuclear factor kappa B (NF-κB), and IL-6 was upregulated at both the messenger RNA (mRNA) and protein levels in a dose-dependent manner when treated with 0, 25, 50, or 100 μg/mL of ox-LDL for 48 h in THP-1 macrophages. Moreover, overexpression of IGF2 significantly upregulated NF-κB and IL-6 expressions in THP-1 macrophages. However, the upregulation of NF-κB and IL-6 expressions induced by ox-LDL were significantly abolished by IGF2 small interfering RNA (siRNA) in THP-1 macrophages. Further studies indicated the upregulation of IL-6 induced by ox-LDL could be abolished when treated with NF-κB siRNA in THP-1 macrophages. Ox-LDL might upregulate IL-6 in the cell and its secretion via enhancing NF-κB in an IGF2-dependent manner in THP-1 macrophages.
Literature
1.
go back to reference Chalmers, A.D., Cohen, A., Bursill, C.A., et al. 2015. Bifurcation and dynamics in a mathematical model of early atherosclerosis: how acute inflammation drives lesion development. J Math Biol. Chalmers, A.D., Cohen, A., Bursill, C.A., et al. 2015. Bifurcation and dynamics in a mathematical model of early atherosclerosis: how acute inflammation drives lesion development. J Math Biol.
2.
go back to reference Sadat, U., F.A. Jaffer, M.A. van Zandvoort, et al. 2014. Inflammation and neovascularization intertwined in atherosclerosis: imaging of structural and molecular imaging targets. Circulation 130: 786–794.PubMedCentralCrossRefPubMed Sadat, U., F.A. Jaffer, M.A. van Zandvoort, et al. 2014. Inflammation and neovascularization intertwined in atherosclerosis: imaging of structural and molecular imaging targets. Circulation 130: 786–794.PubMedCentralCrossRefPubMed
3.
go back to reference Weinberg, E.O., and C.A. Genco. 2012. Directing TRAF-ic: cell-specific TRAF6 signaling in chronic inflammation and atherosclerosis. Circulation 126: 1678–1680.PubMedCentralCrossRefPubMed Weinberg, E.O., and C.A. Genco. 2012. Directing TRAF-ic: cell-specific TRAF6 signaling in chronic inflammation and atherosclerosis. Circulation 126: 1678–1680.PubMedCentralCrossRefPubMed
4.
go back to reference Manduteanu, I., and M. Simionescu. 2012. Inflammation in atherosclerosis: a cause or a result of vascular disorders? Journal of Cellular and Molecular Medicine 16: 1978–1990.PubMedCentralCrossRefPubMed Manduteanu, I., and M. Simionescu. 2012. Inflammation in atherosclerosis: a cause or a result of vascular disorders? Journal of Cellular and Molecular Medicine 16: 1978–1990.PubMedCentralCrossRefPubMed
5.
go back to reference Weber, C., and H. Noels. 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine 17: 1410–1422.CrossRefPubMed Weber, C., and H. Noels. 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine 17: 1410–1422.CrossRefPubMed
6.
go back to reference Chen, J.H., C.W. Tsai, C.P. Wang, et al. 2013. Anti-atherosclerotic potential of gossypetin via inhibiting LDL oxidation and foam cell formation. Toxicology and Applied Pharmacology 272: 313–324.CrossRefPubMed Chen, J.H., C.W. Tsai, C.P. Wang, et al. 2013. Anti-atherosclerotic potential of gossypetin via inhibiting LDL oxidation and foam cell formation. Toxicology and Applied Pharmacology 272: 313–324.CrossRefPubMed
7.
go back to reference Bobryshev, Y.V. 2006. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 37: 208–222.CrossRefPubMed Bobryshev, Y.V. 2006. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 37: 208–222.CrossRefPubMed
8.
go back to reference Lu, J., S. Mitra, X. Wang, et al. 2011. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxidants and Redox Signaling 15: 2301–2333.CrossRefPubMed Lu, J., S. Mitra, X. Wang, et al. 2011. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxidants and Redox Signaling 15: 2301–2333.CrossRefPubMed
9.
go back to reference Sukhanov, S., Y. Higashi, S.Y. Shai, et al. 2007. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2684–2690.CrossRefPubMed Sukhanov, S., Y. Higashi, S.Y. Shai, et al. 2007. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2684–2690.CrossRefPubMed
10.
go back to reference LeRoith, D., and C.T. Roberts Jr. 2003. The insulin-like growth factor system and cancer. Cancer Letters 195: 127–137.CrossRefPubMed LeRoith, D., and C.T. Roberts Jr. 2003. The insulin-like growth factor system and cancer. Cancer Letters 195: 127–137.CrossRefPubMed
11.
go back to reference Higashi, Y., S. Sukhanov, A. Anwar, et al. 2012. Aging, atherosclerosis, and IGF-1. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 67: 626–639.CrossRefPubMed Higashi, Y., S. Sukhanov, A. Anwar, et al. 2012. Aging, atherosclerosis, and IGF-1. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 67: 626–639.CrossRefPubMed
12.
13.
go back to reference Zaina, S., L. Pettersson, B. Ahren, et al. 2002. Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model. The Journal of Biological Chemistry 277: 4505–4511.CrossRefPubMed Zaina, S., L. Pettersson, B. Ahren, et al. 2002. Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model. The Journal of Biological Chemistry 277: 4505–4511.CrossRefPubMed
14.
go back to reference Sun, Y., D. Chen, L. Cao, et al. 2013. MiR-490-3p modulates the proliferation of vascular smooth muscle cells induced by ox-LDL through targeting PAPP-A. Cardiovascular Research 100: 272–279.CrossRefPubMed Sun, Y., D. Chen, L. Cao, et al. 2013. MiR-490-3p modulates the proliferation of vascular smooth muscle cells induced by ox-LDL through targeting PAPP-A. Cardiovascular Research 100: 272–279.CrossRefPubMed
15.
go back to reference Li, S.F., Y.W. Hu, J.Y. Zhao, et al. 2015. Ox-LDL upregulates CRP expression through the IGF2 pathway in THP-1 macrophages. Inflammation 38: 576–583.CrossRefPubMed Li, S.F., Y.W. Hu, J.Y. Zhao, et al. 2015. Ox-LDL upregulates CRP expression through the IGF2 pathway in THP-1 macrophages. Inflammation 38: 576–583.CrossRefPubMed
16.
go back to reference Fontes, J.A., Rose, N.R., Cihakova, D. 2015. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. Fontes, J.A., Rose, N.R., Cihakova, D. 2015. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine.
17.
go back to reference Interleukin-6 Receptor Mendelian Randomisation Analysis, C. 2012. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 379: 1214–1224.CrossRef Interleukin-6 Receptor Mendelian Randomisation Analysis, C. 2012. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 379: 1214–1224.CrossRef
18.
go back to reference Collaboration, I.R.G.C.E.R.F, N. Sarwar, A.S. Butterworth, et al. 2012. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379: 1205–1213.CrossRef Collaboration, I.R.G.C.E.R.F, N. Sarwar, A.S. Butterworth, et al. 2012. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379: 1205–1213.CrossRef
19.
go back to reference Bekkering, S., J. Quintin, L.A. Joosten, et al. 2014. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology 34: 1731–1738.CrossRefPubMed Bekkering, S., J. Quintin, L.A. Joosten, et al. 2014. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology 34: 1731–1738.CrossRefPubMed
20.
go back to reference Kaplanski, G., V. Marin, F. Montero-Julian, et al. 2003. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends in Immunology 24: 25–29.CrossRefPubMed Kaplanski, G., V. Marin, F. Montero-Julian, et al. 2003. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends in Immunology 24: 25–29.CrossRefPubMed
21.
go back to reference Hurst, S.M., T.S. Wilkinson, R.M. McLoughlin, et al. 2001. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705–714.CrossRefPubMed Hurst, S.M., T.S. Wilkinson, R.M. McLoughlin, et al. 2001. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705–714.CrossRefPubMed
22.
go back to reference Toyras, A., J. Ollikainen, M. Taskinen, et al. 2003. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. European Journal of Pharmaceutical Sciences 19: 223–230.CrossRefPubMed Toyras, A., J. Ollikainen, M. Taskinen, et al. 2003. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. European Journal of Pharmaceutical Sciences 19: 223–230.CrossRefPubMed
23.
go back to reference Cao, Q., Y. Jiang, J. Shi, et al. 2015. Artemisinin inhibits the proliferation, migration, and inflammatory reaction induced by tumor necrosis factor-alpha in vascular smooth muscle cells through nuclear factor kappa B pathway. The Journal of Surgical Research 194: 667–678.CrossRefPubMed Cao, Q., Y. Jiang, J. Shi, et al. 2015. Artemisinin inhibits the proliferation, migration, and inflammatory reaction induced by tumor necrosis factor-alpha in vascular smooth muscle cells through nuclear factor kappa B pathway. The Journal of Surgical Research 194: 667–678.CrossRefPubMed
24.
go back to reference de Winther, M.P., E. Kanters, G. Kraal, et al. 2005. Nuclear factor kappaB signaling in atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 904–914.CrossRefPubMed de Winther, M.P., E. Kanters, G. Kraal, et al. 2005. Nuclear factor kappaB signaling in atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 904–914.CrossRefPubMed
25.
go back to reference Hayden, M.S., and S. Ghosh. 2012. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes and Development 26: 203–234.PubMedCentralCrossRefPubMed Hayden, M.S., and S. Ghosh. 2012. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes and Development 26: 203–234.PubMedCentralCrossRefPubMed
26.
go back to reference Wu, Y., W. Zhang, W. Liu, et al. 2011. The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent. Atherosclerosis 215: 170–175.CrossRefPubMed Wu, Y., W. Zhang, W. Liu, et al. 2011. The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent. Atherosclerosis 215: 170–175.CrossRefPubMed
27.
go back to reference Han, C.Y., S.Y. Park, and Y.K. Pak. 2000. Role of endocytosis in the transactivation of nuclear factor-kappaB by oxidized low-density lipoprotein. The Biochemical Journal 350(Pt 3): 829–837.PubMedCentralCrossRefPubMed Han, C.Y., S.Y. Park, and Y.K. Pak. 2000. Role of endocytosis in the transactivation of nuclear factor-kappaB by oxidized low-density lipoprotein. The Biochemical Journal 350(Pt 3): 829–837.PubMedCentralCrossRefPubMed
28.
go back to reference Li, D., T. Saldeen, F. Romeo, et al. 2000. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 102: 1970–1976.CrossRefPubMed Li, D., T. Saldeen, F. Romeo, et al. 2000. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 102: 1970–1976.CrossRefPubMed
29.
go back to reference Hernandez-Presa, M., C. Bustos, M. Ortego, et al. 1997. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95: 1532–1541.CrossRefPubMed Hernandez-Presa, M., C. Bustos, M. Ortego, et al. 1997. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95: 1532–1541.CrossRefPubMed
30.
go back to reference Maziere, C., and J.C. Maziere. 2009. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radical Biology and Medicine 46: 127–137.CrossRefPubMed Maziere, C., and J.C. Maziere. 2009. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radical Biology and Medicine 46: 127–137.CrossRefPubMed
31.
go back to reference Hu, Y.W., J.Y. Yang, X. Ma, et al. 2014. A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis. The Journal of Lipid Research 55: 681–697.CrossRefPubMed Hu, Y.W., J.Y. Yang, X. Ma, et al. 2014. A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis. The Journal of Lipid Research 55: 681–697.CrossRefPubMed
33.
go back to reference Scholz, H., W. Sandberg, J.K. Damas, et al. 2005. Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis. Circulation 112: 2121–2129.CrossRefPubMed Scholz, H., W. Sandberg, J.K. Damas, et al. 2005. Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis. Circulation 112: 2121–2129.CrossRefPubMed
34.
go back to reference Zhang, Q., A.Z. Sha Ma, C. Wang, et al. 2015. Nifedipine inhibits ox-LDL-induced lipid accumulation in human blood-derived macrophages. Biochemical and Biophysical Research Communications 457: 440–444.CrossRefPubMed Zhang, Q., A.Z. Sha Ma, C. Wang, et al. 2015. Nifedipine inhibits ox-LDL-induced lipid accumulation in human blood-derived macrophages. Biochemical and Biophysical Research Communications 457: 440–444.CrossRefPubMed
35.
go back to reference Gomez-Hernandez, A., O. Escribano, L. Perdomo, et al. 2013. Implication of insulin receptor a isoform and IRA/IGF-IR hybrid receptors in the aortic vascular smooth muscle cell proliferation: role of TNF-alpha and IGF-II. Endocrinology 154: 2352–2364.CrossRefPubMed Gomez-Hernandez, A., O. Escribano, L. Perdomo, et al. 2013. Implication of insulin receptor a isoform and IRA/IGF-IR hybrid receptors in the aortic vascular smooth muscle cell proliferation: role of TNF-alpha and IGF-II. Endocrinology 154: 2352–2364.CrossRefPubMed
36.
go back to reference Sukhanov, S., P. Snarski, C. Vaughn, et al. 2015. Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase. Atherosclerosis 238: 313–320.CrossRefPubMed Sukhanov, S., P. Snarski, C. Vaughn, et al. 2015. Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase. Atherosclerosis 238: 313–320.CrossRefPubMed
37.
go back to reference Andersson, P., T. Gustafsson, and H.J. Arnqvist. 1999. Insulin-like growth factor binding proteins-2 to -6 are expressed by human vascular smooth muscle cells. The Journal of Endocrinology 163: 281–288.CrossRefPubMed Andersson, P., T. Gustafsson, and H.J. Arnqvist. 1999. Insulin-like growth factor binding proteins-2 to -6 are expressed by human vascular smooth muscle cells. The Journal of Endocrinology 163: 281–288.CrossRefPubMed
38.
go back to reference Paule, B., S. Terry, L. Kheuang, et al. 2007. The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World Journal of Urology 25: 477–489.CrossRefPubMed Paule, B., S. Terry, L. Kheuang, et al. 2007. The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World Journal of Urology 25: 477–489.CrossRefPubMed
39.
go back to reference Keller, E.T., C. Chang, and W.B. Ershler. 1996. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. The Journal of Biological Chemistry 271: 26267–26275.CrossRefPubMed Keller, E.T., C. Chang, and W.B. Ershler. 1996. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. The Journal of Biological Chemistry 271: 26267–26275.CrossRefPubMed
Metadata
Title
Ox-LDL Upregulates IL-6 Expression by Enhancing NF-κB in an IGF2-Dependent Manner in THP-1 Macrophages
Authors
Yan-Chao Wang
Yan-Wei Hu
Yan-Hua Sha
Ji-Juan Gao
Xin Ma
Shu-Fen Li
Jia-Yi Zhao
Yu-Rong Qiu
Jing-Bo Lu
Chuan Huang
Jing-Jing Zhao
Lei Zheng
Qian Wang
Publication date
01-12-2015
Publisher
Springer US
Published in
Inflammation / Issue 6/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-015-0194-1

Other articles of this Issue 6/2015

Inflammation 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.